Heat Biologics, Inc.
(NASDAQ : HTBX)

( )
HTBX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.43%203.201.2%$410.88m
GILDGilead Sciences, Inc.
0.29%73.880.9%$388.27m
CELGCelgene Corporation
-0.26%87.381.2%$331.13m
BIIBBiogen Inc.
0.60%338.911.2%$285.04m
ILMNIllumina, Inc.
-0.15%350.373.5%$238.24m
REGNRegeneron Pharmaceuticals, Inc.
-1.19%383.702.6%$211.99m
EXASExact Sciences Corporation
1.90%74.1425.3%$196.59m
VRTXVertex Pharmaceuticals Incorporated
-0.29%176.601.9%$158.10m
SRPTSarepta Therapeutics, Inc.
-1.06%151.9516.4%$124.69m
AAgilent Technologies, Inc.
0.93%69.571.5%$120.73m
ALXNAlexion Pharmaceuticals, Inc.
0.95%121.972.0%$110.07m
VKTXViking Therapeutics, Inc.
0.98%19.650.9%$100.12m
NKTRNektar Therapeutics
-2.81%56.695.6%$93.69m
ALNYAlnylam Pharmaceuticals, Inc
1.14%94.829.7%$93.23m
BMRNBioMarin Pharmaceutical Inc.
0.21%99.774.4%$92.72m

Company Profile

Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The firm's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the firm's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Durham, NC.